↓ Skip to main content

Dove Medical Press

Article Metrics

Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine

Overview of attention for article published in Therapeutics and Clinical Risk Management, April 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
9 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
67 Mendeley
Title
Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine
Published in
Therapeutics and Clinical Risk Management, April 2016
DOI 10.2147/tcrm.s105189
Pubmed ID
Authors

De Yun Wang, Xue Yan Wang, Margaret Lim-Jurado, Narayanan Prepageran, Pongsakorn Tantilipikorn

Abstract

Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients' quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug-drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug's safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 67 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 18%
Researcher 10 15%
Student > Master 6 9%
Student > Postgraduate 6 9%
Student > Ph. D. Student 6 9%
Other 13 19%
Unknown 14 21%
Readers by discipline Count As %
Medicine and Dentistry 23 34%
Biochemistry, Genetics and Molecular Biology 8 12%
Pharmacology, Toxicology and Pharmaceutical Science 8 12%
Agricultural and Biological Sciences 7 10%
Economics, Econometrics and Finance 2 3%
Other 5 7%
Unknown 14 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2018.
All research outputs
#3,071,712
of 12,582,044 outputs
Outputs from Therapeutics and Clinical Risk Management
#154
of 928 outputs
Outputs of similar age
#70,871
of 263,614 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 54 outputs
Altmetric has tracked 12,582,044 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 928 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,614 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.